GlycoMimetics Performance
| GLYCDelisted Stock | USD 0.16 0.01 5.88% |
The company retains a Market Volatility (i.e., Beta) of -418.01, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning GlycoMimetics are expected to decrease by larger amounts. On the other hand, during market turmoil, GlycoMimetics is expected to outperform it. GlycoMimetics right now retains a risk of 0.0%. Please check out GlycoMimetics potential upside and the relationship between the skewness and price action indicator , to decide if GlycoMimetics will be following its current trending patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days GlycoMimetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, GlycoMimetics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 41.8 M | |
| Free Cash Flow | -31.1 M |
GlycoMimetics |
GlycoMimetics Relative Risk vs. Return Landscape
If you would invest 16.00 in GlycoMimetics on November 30, 2025 and sell it today you would earn a total of 0.00 from holding GlycoMimetics or generate 0.0% return on investment over 90 days. GlycoMimetics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than GlycoMimetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GlycoMimetics Target Price Odds to finish over Current Price
The tendency of GlycoMimetics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.16 | 90 days | 0.16 | about 60.66 |
Based on a normal probability distribution, the odds of GlycoMimetics to move above the current price in 90 days from now is about 60.66 (This GlycoMimetics probability density function shows the probability of GlycoMimetics Stock to fall within a particular range of prices over 90 days) .
GlycoMimetics Price Density |
| Price |
Predictive Modules for GlycoMimetics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GlycoMimetics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GlycoMimetics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GlycoMimetics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. GlycoMimetics is not an exception. The market had few large corrections towards the GlycoMimetics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GlycoMimetics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GlycoMimetics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 170.73 | |
β | Beta against Dow Jones | -418.01 | |
σ | Overall volatility | 4.03 | |
Ir | Information ratio | 0.12 |
GlycoMimetics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GlycoMimetics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GlycoMimetics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GlycoMimetics is now traded under the symbol CBIO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| GlycoMimetics is not yet fully synchronised with the market data | |
| GlycoMimetics has some characteristics of a very speculative penny stock | |
| GlycoMimetics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (37.88 M) with profit before overhead, payroll, taxes, and interest of 10 K. | |
| GlycoMimetics currently holds about 60.24 M in cash with (31.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
GlycoMimetics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GlycoMimetics Stock often depends not only on the future outlook of the current and potential GlycoMimetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GlycoMimetics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 64.5 M | |
| Cash And Short Term Investments | 10.7 M |
GlycoMimetics Fundamentals Growth
GlycoMimetics Stock prices reflect investors' perceptions of the future prospects and financial health of GlycoMimetics, and GlycoMimetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlycoMimetics Stock performance.
| Return On Equity | -1.83 | |||
| Return On Asset | -0.74 | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 64.53 M | |||
| Price To Earning | (7.99) X | |||
| Price To Book | 300.17 X | |||
| Price To Sales | 1,095 X | |||
| EBITDA | (37.84 M) | |||
| Cash And Equivalents | 60.24 M | |||
| Cash Per Share | 1.15 X | |||
| Total Debt | 66.84 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.05 X | |||
| Cash Flow From Operations | (31.1 M) | |||
| Earnings Per Share | (46.00) X | |||
| Total Asset | 11.09 M | |||
| Retained Earnings | (494.36 B) | |||
| Current Asset | 46.52 M | |||
| Current Liabilities | 5.42 M | |||
About GlycoMimetics Performance
By analyzing GlycoMimetics' fundamental ratios, stakeholders can gain valuable insights into GlycoMimetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GlycoMimetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GlycoMimetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Glycomimetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people.Things to note about GlycoMimetics performance evaluation
Checking the ongoing alerts about GlycoMimetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlycoMimetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GlycoMimetics is now traded under the symbol CBIO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| GlycoMimetics is not yet fully synchronised with the market data | |
| GlycoMimetics has some characteristics of a very speculative penny stock | |
| GlycoMimetics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (37.88 M) with profit before overhead, payroll, taxes, and interest of 10 K. | |
| GlycoMimetics currently holds about 60.24 M in cash with (31.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing GlycoMimetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlycoMimetics' stock is overvalued or undervalued compared to its peers.
- Examining GlycoMimetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlycoMimetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlycoMimetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlycoMimetics' stock. These opinions can provide insight into GlycoMimetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in GlycoMimetics Stock
If you are still planning to invest in GlycoMimetics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GlycoMimetics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |